Decibel Announces Third Quarter Results with $30.2 Million of Net Revenue
Revolutionary Rick Simpson Oil Now Widely Available in Canada
COMPARING MILITARY CONCEPTS OF MODERN WARFARE TO THE 1986 BOOK “SILENT WEAPONS FOR QUIET WARS”
COMPARING MILITARY CONCEPTS OF MODERN WARFARE
TO THE 1986 BOOK “SILENT WEAPONS FOR QUIET WARS”
The 1986 manual outlines a plan to control the masses through manipulation of industry, education and politics, and to divert the public’s attention from what is really going on.
Modern concepts of warfare focus primarily around battles over ideas, information and perception, using non-kinetic military actions, “soft power,” social engineering, propaganda, cyberattacks and emerging technologies such as artificial intelligence (AI) deployed from online/offline “bots” or mechanisms acting mostly outside of human control.
Curiously enough, most of these techniques, except perhaps for the AI bots, were originally used by civilians as part of the normal municipal, provincial and federal political process to choose leaders and set policy.
Those non-violent tools are now being defined by the military as “weapons of war.” Anyone using them risks being defined as an “enemy combatant” or a terrorist.
The reasons for this change are simple and easy to understand. There was once, as outlined in the July 14th, 2013 Financial Post article, “US Repeals Propaganda Ban, Spreads Government-Made News to Americans,” legislation on the books forbidding the US government from using at least some of these techniques on its own citizens.
That legislation didn’t forbid political parties or the private sector from using the techniques and giant advertising agencies grew up around the utilization of these concepts to sell soap and other retail products.
But western government were allowed to use them against their own citizens, at least until 2013 in the US.
Canada is somewhat different, although the end result is the same. Since 1993, the Canadian Armed Forces has also provided the country’s federal counter-terrorism forces, replacing the Royal Canadian Mounted Police in that function, although its actions are officially subject to civilian oversight.
Posts like the June 24th, 2021 Global News post, “China, Russia exploiting high-tech in ‘hybrid warfare’ costs up to $100B per year in Canada: report,” suggest that, while Canada’s military would like to develop a capacity to compete in the battles over ideas, information and perception, it isn’t able to do so currently.
But, and like almost everyone else, the “stakeholders” of our current system know damn well that they possess “overwhelming force” in any conventional “kinetic military action” involving active warfare and lethal force, but also realize that they have often been thwarted over the last five decades by small groups of knowledgeable, savvy people with compelling ideas and an understanding of the new concepts.
So western militaries in both the US and Canada are now allowed to operate against their civilian populations, a situation traditionally considered anathema to the democratic process. The EU, Australia and other western nations have instituted similar processes over the last two decades which have also allowed their governments to use “non-kinetic concepts” to spy on and influence their domestic populace.
Curiously enough, those “non-kinetic concepts” have a lot in common with the ideas discussed in the book, “Silent Weapons for Quiet Wars, An Introductory Programming Manual,” supposedly a “top secret manual” allegedly found by accident in 1986 in a surplus IBM copier sold for scrap parts to a Boeing employee.
According to the Amazon overview of the book:
The manual outlines a plan to control the masses through manipulation of industry, education and politics, and to divert the public’s attention from what is really going on.
Surprisingly, it is claimed that much of what is outlined has come to pass, and makes interesting reading for those exploring the deeper levels of our social structure and how it may be controlled or influenced.
A more recent and more official overview of this topic, is the undated “5th Generation Warfare; Understanding the 5th Generation Mission Space,” published by UK based 360iSR, a privately held company set up in 2013 by Ewen Stockbridge to focus on Western military intelligence support contracts related to unmanned aerial vehicles plus military intelligence, surveillance and reconnaissance (ISR) capabilities.
The 360iSR document begins with a discussion of past US intelligence failures:
Eight years into the war in Afghanistan, the U.S. intelligence community is only marginally relevant to the overall strategy.
Having focused the overwhelming majority of its collection efforts and analytical brainpower on insurgent groups, the vast intelligence apparatus is unable to answer fundamental questions about the environment in which U.S. and allied forces operate and the people they seek to persuade.”
Some of the best recent work on non-kinetic warfare comes to us via the Indian subcontinent, where stories like the January 19th, 2022 Pakistan Politico post, “Mapping the Blurring Lines of Warfare and Diplomacy,” noted the blurring of traditional warfare concepts into the concept of “warfare by other means.”
That concept was also explored by author Peter Stiff in his 2001 book, “Warfare by Other Means: South Africa in the 1980’s and 1990’s,” which explored the highly unconventional warfare conducted by South Africa’s secret intelligence and covert warfare units during the final years of apartheid.
For more on this topic, check out:
1. Use your affiliate link for either Healing Support promo or for Heartmend promo.
2. When the customer enters the floralive site (thru your link) they must add EITHER
A. add 3 Healing Support (combination essence) and 3 Blue Eyed Grass to the shopping cart, then go to checkout and enter the coupon code for this promo which is: HSHOLIDAYS (not case sensitive).
This will charge them for the Healing Support and they will get the Blue Eyed Grass free
Or
B. Add 6 Heartmend to shopping cart, go to checkout, there will be a charge for 4 Heartmend and two free when the coupon code HMHOLIDAYS is used.
420 with CNW — Lawsuits, Elections Could Impact Cannabis Rescheduling Timeline
With both the White House and Senate in the hands of the Democrats, the chances of federal cannabis legalization becoming a reality have skyrocketed. President Joe Biden based part of his campaign on cannabis reform, and his administration’s Department of Health and Human Services (HHS) recently issued a recommendation to the U.S. Drug Enforcement Administration to loosen cannabis restrictions on the federal level.
However, even though the current administration is throwing its weight behind cannabis reform and the DEA is likely to abide by HHS’ recommendation, lawsuits and elections may impact the timeline for federal cannabis rescheduling.
Many drug reform proponents had little faith in President Biden fulfilling his cannabis promises once he assumed office. After all, Biden was instrumental in escalating the drug war back when he was a senator, and he had made his opposition to recreational marijuana clear in his old age.
His administration’s decision to recommend cannabis rescheduling was a welcome surprise and was the first time the U.S. federal government acknowledged that cannabis had medicinal value. Based on the Controlled Substances Act and its requirements for drugs classified as Schedule I substances, legal experts say the DEA has no choice but to follow the Biden Administration’s recommendation and reschedule marijuana.
Washington DC-based law firm Arnold & Porter partner Howard Sklamberg predicts that the DEA could sign off on the recommendation as early as the end of 2024. Sklamberg, who previously served as a top enforcement official at the Food and Drug Administration (FDA), also predicted that the HHS would issue a cannabis rescheduling recommendation faster than expected.
He says the DEA will likely have a completed final rule by 2024. If American voters choose President Biden for a second term, observers say the nation may be even close to federal legalization and interstate cannabis trade. Ironically, such an outcome would mean that Biden, chief sponsor of the controversial 1994 crime bill that reportedly contributed to the mass incarceration of nonviolent drug offenders, would be instrumental in finally ending the era of cannabis prohibition in the United States.
Biden’s administration began acting on its cannabis promises later than many would have liked, but it seems to be taking cannabis reform quite seriously. Even so, observers note that lawsuits from reform proponents seeking comprehensive reform and opponents looking to keep cannabis illegal will derail efforts to reschedule the plant at the federal level.
Such lawsuits could hold up the rescheduling process until the suits are resolved or even leave the decision to reschedule cannabis entirely in the hands of the U.S. Supreme Court. This will stretch out the timeline even further and could be a disadvantage to industry enterprises such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) that have been looking forward to policy changes at the federal level.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
420 with CNW — Report from Illinois Highlights Significant Diversity Improvements in Cannabis Industry
Recent cannabis data from Illinois has revealed a sharp increase in diversity since the state launched recreational cannabis sales in January 2020. The Illinois Cannabis Regulation Oversight Officer (CROO) states that cannabis businesses in the early days of adult-use sales were 100% majority owned with only one majority woman-owned cannabis enterprise in the entire state.
However, a survey report published last week shows that efforts to promote diversity in the Illinois recreational cannabis industry have yielded great success. The surveys found that the number of Black-owned businesses in the sector increased from 0 27% from 2020 to 2023. Hispanic or Latino-owned businesses went up from 0 to 5%, and Asian-owned enterprises climbed from 0 to 3%. Furthermore, women-owned companies now account for 16% of all licensed cannabis companies in Illinois.
These findings came from two CROO surveys. The first was a mandatory survey sent to all the 277 licensed cannabis businesses in May while the other was a voluntary poll for their employees.
Approximately 224 licensees (132 companies) and 2,307 employees responded to the poll, providing CROO with a decent enough sample size to work with. They found that the number of individual cannabis business owners in the Black community increased to 26% from only 1% in 2020 while Hispanic and Latino owners now account for 7% of the market.
On the employee side, 11% of the survey participants were Hispanic or Latino, a 6% increase from 5% in 2020. However, even though the number of Black employees in the state’s cannabis sector dropped from 10% to 9% in 2023, Black workers were better represented in higher-level positions in 2023 compared to 2020, registering an increase to 19% from a paltry 1% of Black employees in the C-suite. The number of Black people on the boards of directors of cannabis companies also increased from 6% in 2020 to 20% in 2023, the report said.
CROO notes that the findings may not be fully representative of Illinois’ cannabis industry because not every licensed cannabis retailer responded to the poll. The office also added that responses from licensed cannabis companies “were not verified but accepted as accurate.” Even so, CROO says their findings represent the most accurate and available information on the subject matter to date.
Social equity has been a key component of cannabis legalization efforts in many states because it allows communities that were disproportionately harmed by cannabis prohibition to benefit from cannabis legalization.
This report shows the extent to which companies such as Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) are creating opportunities for a diverse set of Illinois residents to participate in this rapidly growing industry.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer
CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is powered by IBN
FDA Guidance on Psychedelic Trials Sparks Debate Regarding Psychological Support’s Role
Psychedelics have been subject to significantly increased attention from the medical and scientific communities in recent years due to claims of their medical efficacy against various mental health conditions. While a majority of psychedelic compounds are still illegal at the federal level and in most states, increasingly promising findings have resulted in at least 100 conferences on psychedelic research and medicine in the United States alone over the past three years.
The main agenda at these events has been how psychedelics and psychedelic-assisted psychotherapy can aid in the treatment of conditions such as anxiety, depression and post-traumatic stress disorder (PTSD).
Regulatory bodies such as the U.S. Food and Drug Administration (FDA) are also poised to approve the use of certain psychedelics in therapeutic settings in the next couple of years, with the FDA issuing a new draft guidance on psychedelic trials in late June. The draft guidance advised researchers on how to construct psychedelic studies to determine their potential as treatments for psychiatric conditions.
While the medical and scientific communities were happy that the FDA was taking action regarding psychedelic research, language regarding the necessity of psychological support during psychedelic therapy has sparked a fierce debate. The FDA’s draft guidance encouraged study sponsors to justify the necessity of psychological support during and after psychedelic administration. Furthermore, it urged sponsors to describe trial design elements that would help reduce potential bias or “quantify the contribution of psychotherapy to the overall treatment effect.”
The regulatory agency’s reservations about psychotherapy come from the belief that it could complicate evaluations of the efficacy of therapeutic psychedelic compounds as well as the labeling of psychedelic treatments. Studies on psychedelic-assisted therapy have found that the talk therapy aspect of the treatment is crucial during the integration stage where patients learn to integrate any realizations and epiphanies they may have made during a guided psychedelic trip.
Some critics say the FDA’s draft guidance on psychedelic trials doesn’t fully understand the role psychological support plays in psychedelic treatments. Many scientists and academics within the psychedelic research space believe that the talk therapy aspect is critical to the success of psychedelic therapy. Additionally, most psychedelic facilitators and practitioners would say that building a rapport between patient and guide is key to optimizing psychedelic treatment outcomes.
Consequently, altering aftercare protocols or eliminating talk therapy entirely would likely reduce patient response rates and limit the treatment’s efficacy.
Tea Petkova, an IFS-trained psychedelic facilitator and holder of a master’s degree in applied cognitive neuroscience says going through the processes of preparation, expansion and integration with one facilitator builds the trust patients need to follow their facilitators’ guidance throughout treatment. Ethically, testing the efficacy of psychedelic treatments without the talk-therapy component should happen on patients with no mental-health diagnoses, Petkova says.
Unfortunately, most of the patients who take part in psychedelic-related studies tend to have diagnoses for one or more mental-health disorders for which they receive psychological support. Limiting their access to psychological support or changing facilitators during treatment could consequently limit the long-term benefits of psychedelic treatments.
Startups that have made significant strides in developing psychedelic medicines such as atai Life Sciences N.V. (NASDAQ: ATAI) may have to give the FDA feedback regarding the best way to leverage psychological support during psychedelic-assisted therapy.
About PsychedelicNewsWire
PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com
PsychedelicNewsWire is powered by IBN
New flower offerings from 7ACRES and Tweed kick off holiday season early
“Our new high-quality flower offerings, including a holiday taster pack from 7ACRES and new strains from the iconic Tweed brand, are the perfect complement to any festive adult celebration. These latest additions to our leading Canadian portfolio reflect our team’s focus and commitment to producing extraordinary flower products and offer consumers a great opportunity to elevate their celebrations during this holiday season.” — Dave Paterson, president, Canopy Growth
7ACRES Holiday Taster Pack
The holidays are arriving early this year with the launch of two flavourful holiday-inspired flower harvests. 7ACRES Holiday Taster Pack (2x7g) 14g featuring strains Ultra Jolly Jack and Peppermint Krypt is now available for purchase.
Ultra Jolly Jack is a Sativa-dominant cross of Jack Haze and Ultra Sour strain lineage, creating a festive aroma that features holiday spices alongside earthy and lemon undertones. Complementing Ultra Jolly Jack is the Indica-dominant hybrid Peppermint Krypt, with its sweet and spicy holiday aromas as well as creamy undertones thanks to the cross between frosty Kush Mints and 91K.
Advertisement
Both strains feature a 24-30 per cent THC range, are hang dried, and packaged with a Boveda pack to ensure freshness, making the 7ACRES Holiday Taster Pack a thoughtful gift for consumers looking for convenience, variety, and a high-quality experience.
Tweed Gorilla Berry and Chemsicle
Given the pressures of the holiday season, Tweed is making it easy to unwind with two new whole flower offerings, Tweed Gorilla Berry and Tweed Chemsicle.
Tweed Gorilla Berry is an Indica whole cannabis flower born from the Frosted Kush x Gorilla and Triangle Kush x Blueberry lineage, and features terpenes Terpinolene, ß-Caryophyllene, and ß-Pinene. Bringing forth the sweetness of the holidays, Tweed Gorilla Berry boasts berry and citrus flavours, a gassy aroma, and a 28-34% THC range, making it a perfect stocking (or pipe) stuffer for those looking for full flavour and superior quality.
Tweed’s Chemiscle is a Sativa whole flower offering creamy, spicy, and earthy flavor and aroma. Derived from 91K and Chemdawg lineage, Chemiscle has a 24-30 per cent THC range with terpenes including ß-Myrcene, ß-Pinene, α-Pinene.
Both strains are packaged with Boveda 2-way humidity control packs and come in 14g whole flower formats.
Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca
(Globe Newswire) Toronto — Avicanna Inc., a biopharmaceutical company focused on the commercialization of proprietary cannabinoid-based products and medical cannabis care platform, is pleased to announce the results of Q3 2023.
“We had the boldness to take on the challenge of acquiring the Medical Cannabis by Shoppers business and executed on integrating it into the newly developed MyMedi.ca to with a goal of being able to offer a comprehensive medical cannabis care platform and improve access for Canadian patients. We have remained dedicated and focused on evidence based medical application of cannabinoids and during this quarter we have solidified our business model and our capability to scale the business.” — Aras Azadian, CEO, Avicanna Inc.
Financial highlights:
— Record revenue of $6.27M, representing an increase of 90 per cent over the previous quarter and 713 per cent over the same period last year.
Advertisement
— A 9-month revenue of $10.7M, representing a major milestone in the dompany’s history a 269 per cent growth from the same period last year.
— Scalability of the business model was demonstrated with a comparable increase of 23 per cent in SG&A for the nine-month period.
— Best three-month financial performance in the company’s history with an adjusted EBITDA loss of $473,000 or loss of $0.01 per share during the third quarter.
— Improved consolidated gross margins of 47 per cent through developments in operational efficiencies.
Phil Cardella, CFO added: “We are extremely proud to have turned the corner and accomplished the major milestone of an eight-digit revenue figure for the first time in the company’s history. The substantial increase in high margin revenue, coupled with improvements in our working capital, and balance sheet are a testament to the company’s innovation and commercial platforms delivering a great portfolio of products and services. We look forward to our own going efforts towards sustainable growth, profitability, and self-reliance.”
Launch of MyMedi.ca medical cannabis care platform: Launch of MyMedi.ca saw over 96 per cent of active patients from Medical Cannabis by Shoppers business transitioned to the company’s new medical cannabis care platform and has since increased its new medical patient base by approximately 10 per cent. The company developed infrastructure to offer insurance reimbursement services for patients through several private insurance providers and public institutions including eight provincial worker safety boards which combined account for over 60 per cent of the platform’s revenue.
The integration of MyMedi.ca’s platform and patient support programs, improved access and enhanced education have resulted an 40 per cent increase of the company’s product sales on the platform when compared to the previous quarter.
Canadian commercial advancements: The launch of new proprietary formulations totalling 27 commercially active SKUs in Canada across 131 listings in medical and adult use channel. Access to the company’s proprietary medical products improved for patients with availability on new medical platforms such as Canna Farms and Spectrum Therapeutics.
Recent Comments